Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zolbetuximab, an antibody targeting Claudin 18.2.

Nested Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Netakimab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Loncastuximab, an antibody targeting CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Leronlimab, an antibody targeting CCR5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Belantamab, an antibody targeting BCMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pabinafusp, an antibody targeting CD71.

Frontier Medicines 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Vividion Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Terremoto Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Eikon Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Clasp Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.